News | March 20, 2024
AstraZeneca buys biopharmaceutical company Fusion
To accelerate the development of next-generation radioconjugates to treat cancer
To accelerate the development of next-generation radioconjugates to treat cancer
XTANDI becomes the first and only androgen receptor signaling inhibitor approved for use with or without a GnRH analog therapy in nonmetastatic castration-sensitive prostate cancer
The first phase of the hospital with 225 beds built over 1.75 lakh square feet will be commissioned in the next 12 months
Dr. Laurent Leksell, Elekta’s Founder and Chairman of the Board, and IAEA’s Director General, Dr. Rafael Mariano Grossi meet in Stockholm to discuss reducing the global cancer burden
KEYTRUDA plus concurrent chemoradiotherapy demonstrated statistically significant and clinically meaningful improvement in PFS versus concurrent chemoradiotherapy alone in these patients
Collaboration to provide hospitals with a comprehensive offering across imaging and treatment for cancer patients requiring radiation therapy
Gafchromic films support patient care in oncology
Spain’s renowned centre of excellence recognises importance of verifying radiosurgery plans ahead of patient treatment
First release of Rs.166 crores incentives under PLI scheme for pharmaceuticals
To bring quality cancer treatment closer to patients, India’s leading MedTech brand is joining forces with the unique technology-led platform
Subscribe To Our Newsletter & Stay Updated
